DE570357T1 - Peptide, die Antikörper induzieren, die genetisch divergierende HIV-1 Isolationen neutralisieren. - Google Patents

Peptide, die Antikörper induzieren, die genetisch divergierende HIV-1 Isolationen neutralisieren.

Info

Publication number
DE570357T1
DE570357T1 DE0570357T DE93890100T DE570357T1 DE 570357 T1 DE570357 T1 DE 570357T1 DE 0570357 T DE0570357 T DE 0570357T DE 93890100 T DE93890100 T DE 93890100T DE 570357 T1 DE570357 T1 DE 570357T1
Authority
DE
Germany
Prior art keywords
peptides according
seq
peptides
fusion
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE0570357T
Other languages
German (de)
English (en)
Inventor
Gottfried A-1180 Vienna Himmler
Hermann A-1190 Vienna Katinger
Georg A-1040 Vienna Maiwald
Thomas A-1180 Vienna Muster
Martin A-1180 Vienna Purtscher
Florian A-1170 Vienna Rueker
Franz A-1160 Vienna Steindl
Alexandra A-1232 Vienna Trkola
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Polymun Scientific Immunbiologische Forschung GmbH
Original Assignee
Polymun Scientific Immunbiologische Forschung GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AT98792A external-priority patent/AT403050B/de
Application filed by Polymun Scientific Immunbiologische Forschung GmbH filed Critical Polymun Scientific Immunbiologische Forschung GmbH
Publication of DE570357T1 publication Critical patent/DE570357T1/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4216—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-viral Ig
    • C07K16/4225—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-viral Ig against anti-HIV Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE0570357T 1992-05-14 1993-05-13 Peptide, die Antikörper induzieren, die genetisch divergierende HIV-1 Isolationen neutralisieren. Pending DE570357T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT98792A AT403050B (de) 1992-05-14 1992-05-14 Peptide, die antikörper binden
US93278792A 1992-08-29 1992-08-29

Publications (1)

Publication Number Publication Date
DE570357T1 true DE570357T1 (de) 1994-07-28

Family

ID=25594514

Family Applications (2)

Application Number Title Priority Date Filing Date
DE0570357T Pending DE570357T1 (de) 1992-05-14 1993-05-13 Peptide, die Antikörper induzieren, die genetisch divergierende HIV-1 Isolationen neutralisieren.
DE69311764T Expired - Lifetime DE69311764T2 (de) 1992-05-14 1993-05-13 Peptide, die Antikörper induzieren, die genetisch divergierende HIV-1 Isolationen neutralisieren

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69311764T Expired - Lifetime DE69311764T2 (de) 1992-05-14 1993-05-13 Peptide, die Antikörper induzieren, die genetisch divergierende HIV-1 Isolationen neutralisieren

Country Status (6)

Country Link
US (3) US5693752A (https=)
EP (1) EP0570357B1 (https=)
JP (1) JP3369246B2 (https=)
CA (1) CA2096159C (https=)
DE (2) DE570357T1 (https=)
ES (1) ES2053413T3 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0580758A4 (en) * 1991-04-18 1995-04-05 Sinai School Medicine RECOMBINANT ANTIBODIES AGAINST HUMAN IMMUNE WEAKNESS VIRUS.
DE570357T1 (de) * 1992-05-14 1994-07-28 Polimun Scientific Immunbiologische Forschungsgesellschaft Mbh, Wien Peptide, die Antikörper induzieren, die genetisch divergierende HIV-1 Isolationen neutralisieren.
DE69426725T2 (de) * 1993-09-11 2001-09-06 Polimun Scientific Immunbiologische Forschungsgesellschaft Mbh, Wien Peptide, die neutralisierende antikörper gegen genetisch divergierende hiv-1 stämme, induzieren
FR2731225B1 (fr) * 1995-03-03 2003-10-31 Pasteur Institut Peptides de glycoproteine transmembranaire d'enveloppe et de proteine de capside du retrovirus humain du type hiv-1 et peptides presentant avec eux une parente immunologique
CN1651457B (zh) 1994-10-20 2010-07-28 巴斯德研究所 Hiv-1 o组(或亚组)逆转录病毒抗原的核苷酸序列
GB9424631D0 (en) * 1994-12-06 1995-01-25 Lynxvale Ltd Modulating the immune response
MX9708008A (es) * 1995-04-19 1998-03-31 Polymun Scient Immunbio Forsch Anticuerpos monoclonales contra vih-1 y vacunas hechas de los mismos.
US5891994A (en) * 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
US6228128B1 (en) 1997-11-10 2001-05-08 Charlotte Johansen Antimicrobial activity of laccases
ATE384126T1 (de) 1998-06-12 2008-02-15 Sinai School Medicine Interferon induzierende genetisch veränderte attenuierte viren
KR100637937B1 (ko) 1998-06-12 2006-10-23 마운트 시나이 스쿨 오브 메디신 오브 뉴욕 유니버시티 변형된 인터페론 길항물질을 보유하고, 백신 및 약제로사용되는 약독화된 네거티브 가닥 바이러스
US7090848B1 (en) 1998-08-04 2006-08-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine HIV-1 envelope protein associated with a broadly reactive neutralizing antibody response
ATE435034T1 (de) * 1998-08-04 2009-07-15 Jackson H M Found Military Med Expression und charakterisierung eines hiv-1 hüllproteins, das mit einer breitreaktiven neutralisierenden antikörperantwort assoziiert ist.
US7115262B1 (en) 1999-03-16 2006-10-03 The United States Of America As Represented By The Department Of Health And Human Services Chimeric protein for prevention and treatment of HIV infection
WO2001077394A1 (en) * 2000-04-10 2001-10-18 Mount Sinai School Of Medicine Of New York University Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
US6399067B1 (en) * 2000-04-28 2002-06-04 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
ATE444310T1 (de) 2002-01-17 2009-10-15 Polymun Scient Immunbio Forsch Antiidiotypische antikörper die hiv-1 neutralisierende antikörper induzieren
EP1627046A4 (en) * 2003-05-06 2008-02-13 Scripps Research Inst BINDING MOLECULES WITH DOMAIN EXCHANGE, USE METHOD AND METHOD OF MANUFACTURE
EP3332803B1 (en) 2004-06-01 2021-09-08 Icahn School of Medicine at Mount Sinai Genetically engineered swine influenza virus and uses thereof
WO2006088481A2 (en) * 2005-02-15 2006-08-24 Mount Sinai School Of Medicine Of New York University Genetically engineered equine influenza virus and uses thereof
US7563437B2 (en) 2005-02-15 2009-07-21 Thymon, Llc Methods and compositions for impairing multiplication of HIV-1
TW200726479A (en) * 2005-04-12 2007-07-16 Univ Duke Method of inducing neutralizing antibodies to human immunodeficiency virus
EP1989326A4 (en) 2006-01-17 2009-09-30 Health Research Inc BIO-HETERODUPLEX TRACKING TEST
EP2139516A4 (en) * 2007-04-13 2011-06-29 Univ Duke METHOD FOR INDUCING NEUTRALIZING ANTIBODY AGAINST HIV
EP2550362B1 (en) 2010-03-25 2017-01-04 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
CA2832109C (en) 2011-06-10 2021-07-06 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
EP2568289A3 (en) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
US10076567B2 (en) 2013-09-27 2018-09-18 Duke University MPER-liposome conjugates and uses thereof
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
JP6722686B2 (ja) 2015-02-26 2020-07-15 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハーＢｏｅｈｒｉｎｇｅｒ Ｉｎｇｅｌｈｅｉｍ Ｖｅｔｍｅｄｉｃａ ＧｍｂＨ 二価ブタインフルエンザウイルスワクチン
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
WO2017093985A1 (en) 2015-12-05 2017-06-08 Centre Hospitalier Universitaire Vaudois Hiv binding agents
WO2020012435A1 (en) 2018-07-13 2020-01-16 Lausanne University Hospital Hiv binding agents
JP7678790B2 (ja) 2019-07-15 2025-05-16 ローザンヌ ユニヴァーシティ ホスピタル Ｈｉｖ結合剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0269712A4 (en) * 1986-06-12 1990-06-26 Biogen Nv PEPTIDES INVOLVED IN THE PATHOGENESIS OF A HIV TYPE INFECTION.
EP0330359A3 (en) * 1988-02-25 1991-06-05 Bio-Rad Laboratories, Inc. Composition useful in the diagnosis and treating of hiv-1 infection
EP0362910A3 (en) * 1988-08-27 1991-01-09 Akzo N.V. Synthetic peptides immunochemically reactive with hiv-antibodies
DE570357T1 (de) * 1992-05-14 1994-07-28 Polimun Scientific Immunbiologische Forschungsgesellschaft Mbh, Wien Peptide, die Antikörper induzieren, die genetisch divergierende HIV-1 Isolationen neutralisieren.

Also Published As

Publication number Publication date
ES2053413T1 (es) 1994-08-01
US5693752A (en) 1997-12-02
US5756674A (en) 1998-05-26
DE69311764D1 (de) 1997-07-31
ES2053413T3 (es) 1997-11-16
EP0570357A3 (https=) 1994-04-20
EP0570357B1 (en) 1997-06-25
US5866694A (en) 1999-02-02
JPH06293797A (ja) 1994-10-21
DE69311764T2 (de) 1998-02-05
JP3369246B2 (ja) 2003-01-20
CA2096159A1 (en) 1993-11-15
CA2096159C (en) 2004-07-20
EP0570357A2 (en) 1993-11-18

Similar Documents

Publication Publication Date Title
DE570357T1 (de) Peptide, die Antikörper induzieren, die genetisch divergierende HIV-1 Isolationen neutralisieren.
KR900701836A (ko) 신규 hiv 단백질 및 aids의 진단, 예방 또는 치료에 유용한 펩티드
RU95122726A (ru) Способ получения иммуногенов или диагностических реагентов, а также иммуногены и диагностические реагенты, получаемые с его помощью
ATE175121T1 (de) Durch pre-s-gen kodierte hepatitis-b-peptid- immunogene, vakzine, diagnostika und synthetische lipid-bläschenträger
CN111732654B (zh) 一种抗SARS-CoV-2的单克隆抗体1E10
MXPA02011163A (es) Anticuerpos igm humanos con la capacidad de inducir remielinacion, y usos diagnosticos y terapeuticos de los mismos particularmente en el sistema nervioso central.
WO2000073430A3 (de) Vakzine gegen konformationsabhängige antigene sowie gegen antigene, die keine oder nicht ausschliesslich proteine oder peptide sind
EP0291636A1 (en) Immune response to viruses induced by anti-idiotype antibodies
CN1610697A (zh) 戊型肝炎病毒单克隆抗体或其结合活性片段及其用途
DE69223250T3 (de) Detektion des immunschwäche-virus aus felis
EP1331271A4 (en) POLYPEPTIDE FRAGMENT OF HEPATITIS E VIRUS, VACCINE COMPOSITION CONTAINING SAID FRAGMENT, DIAGNOSTIC AGENT AND THEIR APPLICATIONS
WO1996021734A3 (en) P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
RU96108781A (ru) Пептиды, создающие нейтрализующие антитела к генетически дифергентным штаммам вич-1
ATE136933T1 (de) Rekombinante hbsag hybridpartikel, die morphologische eigenschaften von hbsag-antigen haben und eine immunogene sequenz enthalten, die neutralisierende antikörper gegen hiv induziert oder die von diesen antikörpern erkannt ist, nukleotide sequenzen, die diese partikel codieren und sie enthaltende impfstoffe
DE69814884T2 (de) Hepatitis b virale polypeptide
DE69106141T2 (de) Non-a non-b sequenzen.
WO1996009391A3 (en) Dna sequence and protein of the non-structural reading frame i of the human parvovirus b19
DE3887521T2 (de) Durch virusneutralisierende und schützende monokonale antikörper erkanntes ibdv vp2 epitop.
DE69200512T2 (de) Mit Antikörper gegen Hepatitis non-A, non-B-Virus immunochemische reaktive Peptide.
DE68926813T2 (de) Von gemeinsamen sequenzen von antigenen und antiidiotypischen antikörpern oder von antikörpern mit spezifizität für die zellulären rezeptoren der antigene abgeleitete immunogene und biologisch aktive peptide
Hopp Computer prediction of protein surface features and antigenic determinants
AU619477B2 (en) Ibdv vp2 epitope recognised by virus neutralising and protective monoclonal antibodies
EP0419446B1 (de) Komplex geeignet zur Durchführung eines Verfahrens zur Reinigung von pre-S-Hepatitis-B-Virus-Oberflächenantigen
ATE79638T1 (de) Polypeptide, deren kodierende peptide und methode zur herstellung dieser peptide und dnas.
US20060275309A1 (en) Peptide oligomers for use as hiv vaccines